Quarterly report pursuant to Section 13 or 15(d)

Organization and Principal Activities - Additional Information (Details)

v3.23.2
Organization and Principal Activities - Additional Information (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2023
USD ($)
Segment
shares
Dec. 31, 2022
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Date of incorporation   Apr. 21, 2003  
Headquartered in   South San Francisco  
Headquartered in state   CA  
Number of operating segments | Segment   1  
Accumulated deficit $ 541,189 $ 541,189 $ 452,615
Unrestricted cash, cash equivalents and marketable securities 358,300 $ 358,300  
Substantial doubt about going concern, within one year   false  
Vaxcyte      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Unrestricted cash, cash equivalents and equity securities at carrying value $ 33,300 $ 33,300  
At-the-Market (“ATM") | Common Stock      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Shares of common stock | shares 216,036 1,857,410  
Gross proceeds from issuance of common stock $ 1,200 $ 12,400  
Underwriting discounts and commissions and other offering expenses 200 400  
Net proceeds from issuance of common stock $ 1,000 $ 12,000  
Minimum      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Period from issuance date of unaudited interim condensed financial statements   12 months